Proteomic and lipidomic biomarkers in the diagnosis and progression of inflammatory bowel disease – a review

Abstract

Purpose There is an increasing prevalence of inflammatory bowel disease (IBD) and to date, no effective treatment has been developed and the exact etiology of this disease remains unknown. Nevertheless, a growing number of proteomic and lipidomic studies have identified certain proteins and lipids which can be used successfully in patients to improve diagnoses and monitoring of treatment. Experimental Design We have focused on the applications of proteins and lipids for IBD diagnostics, including differentiation of Crohn's disease (CD) and ulcerative colitis (UC), treatment monitoring, monitoring of clinical state, likelihood of relapse, and their potential for novel targeted treatments. Results Analysis of protein and lipid profiles can: improve the availability and use of diagnostic markers; improve understanding of the pathomechanisms of IBD, for example, several studies have implicated platelet dysfunction (PF4), autoimmune responses (granzyme B, perforin), and abnormal metabolism (arachidonic acid pathways); aid in monitoring patient health; and improve therapeutics (experimental phosphatidylcholine therapy has been shown to result in an improvement in intestinal condition). Conclusions Despite the enormous progress of proteomics and lipidomics in recent years and the development of new technologies, further research is needed to select some of the most sensitive and specific markers applicable in diagnosing and treating IBD.

Are We Ready to Reclassify Crohn’s Disease Using Molecular Classification?

“…These studies have identified a large variety of lipids associated with CD. However, only a few studies have overlapped in the analysis of specific lipids [ 137 ]. There is also no consensus on the best specimen for analysis in the current literature—blood, tissue or faeces—which have varying levels of invasiveness and ease of collection [ 138 ].…”